---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-002956"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2022-03-07T23:59:59+00:00"
generated_at: "2026-06-27T01:04:49.059619+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# KalVista initiates Phase 3 KONFIDENT trial of KVD900 for HAE attacks

## Summary
- KVD900 is first potential oral on-demand therapy for HAE; all current on-demand therapies are injectable.
- Trial is double-blind, placebo-controlled, crossover; two doses (300 mg, 600 mg) vs placebo.
- Primary endpoint: time to beginning of symptom relief per Patient Global Impression of Change (PGI-C) scale.
- Enrollment: minimum 84 adolescent and adult patients at ~60 sites in 20 countries.
- Top-line data expected in second half of 2023.

## SEC filing metadata
- accession: 0000950170-22-002956
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2022-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017022002956/0000950170-22-002956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017022002956/kalv-20220307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-002956
- JSON: https://secwatch.observer/filing/0000950170-22-002956.json
- Plain text: https://secwatch.observer/filing/0000950170-22-002956.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.